Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,404.80
(
1.34%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
99.58
(
-1.61%
)
Bitcoin
78,237.64
(
-0.05%
)
News Focus
News Focus
Post# of 257442
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122884
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 236582

Friday, 01/08/2021 9:01:23 AM

Friday, January 08, 2021 9:01:23 AM

Post# of 257442
ENTA announces two new programs: 1) an oral HBV RNA destablizer; and 2) an RSV-L inhibitor. These are possible combination agents for ENTA’s existing compounds, EDP-514 and EDP-938, respectively.

https://www.enanta.com/investors/news-releases/press-release/2021/Enanta-Pharmaceuticals-to-Provide-Updates-on-its-Research-and-Development-Programs-and-Outlook-for-2021-at-the-39th-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up